Frank L. J. Visseren, MD, PhD, Department of Vascular Medicine, University Medical Center Utrecht, PO Box 85500, 3508 GA Utrecht, the Netherlands. Tel.: +31 88 7555555; fax: +31 88 7555488; e-mail: [email protected]

Read the full text

About

PDF

Tools

Share a link

Email
Facebook
Twitter
LinkedIn
Reddit
Wechat

Abstract

Eur J Clin Invest 2011; 41 (2): 159–166

Background Visceral adiposity is associated with cardiovascular risk factors and increased cardiovascular risk. Thyroid-stimulating hormone (TSH) levels in the normal range are associated with a higher risk of fatal coronary artery disease. We hypothesize that TSH levels in the normal range are associated with an increase in visceral adipose tissue (VAT) in patients with vascular diseases.

Design In 2419 patients with vascular diseases, visceral fat thickness was analysed with ultrasonography. The association between TSH and VAT was quantified using linear regression analysis. Results are expressed as beta (β) regression coefficients with 95% confidence intervals. Adjustments were made for age, sex, current smoking and weight. Separate analyses were performed per quartile of age.

Results β-coefficients for the relation between TSH and VAT (change per SD of 2·55 cm) was 0·085 (95% CI 0·012–0·157) in the highest quartile of age (range 67–80 years) when adjusted for age, gender and current smoking and remained statistical significant after further adjustment for weight (β 0·096 95% CI 0·034–0·157). Per SD change, the β-coefficient for TSH and VAT tissue was larger than for other measures of adiposity.

Conclusions In conclusion, higher TSH plasma levels in the normal range are associated with more VAT in patients with manifest vascular disease above the age of 66 years. No association was found between plasma TSH levels and weight or BMI. The relation between TSH levels and VAT may provide an explanation for the increased cardiovascular risk associated with elevated TSH plasma concentrations within the normal range.

References

1 Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983; 67: 968–77.
10.1161/01.CIR.67.5.968
CASPubMedWeb of Science®Google Scholar
2 Festa A, D’Agostino R Jr, Williams K, Karter AJ, Mayer-Davis EJ, Tracy RP et al. The relation of body fat mass and distribution to markers of chronic inflammation. Int J Obes Relat Metab Disord 2001; 25: 1407–15.
10.1038/sj.ijo.0801792
CASPubMedWeb of Science®Google Scholar
3 Zamboni M, Armellini F, Turcato E, Micciolo R, Desideri S, Bergamo-Andreis IA et al. Effect of regain of body weight on regional body fat distribution: comparison between pre- and postmenopausal obese women. Obes Res 1996; 4: 555–60.
10.1002/j.1550-8528.1996.tb00269.x
CASPubMedWeb of Science®Google Scholar
4 Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004; 145: 2273–82.
10.1210/en.2003-1336
CASPubMedWeb of Science®Google Scholar
5 Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003; 289: 76–9.
10.1001/jama.289.1.76
PubMedWeb of Science®Google Scholar
6 Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 2005; 366: 1640–9.
10.1016/S0140-6736(05)67663-5
PubMedWeb of Science®Google Scholar
7 Tzotzas T, Krassas GE, Konstantinidis T, Bougoulia M. Changes in lipoprotein(a) levels in overt and subclinical hypothyroidism before and during treatment. Thyroid 2000; 10: 803–8.
10.1089/thy.2000.10.803
CASPubMedWeb of Science®Google Scholar
8 Fox CS, Pencina MJ, D’Agostino RB, Murabito JM, Seely EW, Pearce EN et al. Relations of thyroid function to body weight: cross-sectional and longitudinal observations in a community-based sample. Arch Intern Med 2008; 168: 587–92.
10.1001/archinte.168.6.587
PubMedWeb of Science®Google Scholar
9 Asvold BO, Bjoro T, Nilsen TI, Gunnell D, Vatten LJ. Thyrotropin levels and risk of fatal coronary heart disease: the HUNT study. Arch Intern Med 2008; 168: 855–60.
10.1001/archinte.168.8.855
PubMedWeb of Science®Google Scholar
10 Haraguchi K, Shimura H, Lin L, Saito T, Endo T, Onaya T. Functional expression of thyrotropin receptor in differentiated 3T3-L1 cells: a possible model cell line of extrathyroidal expression of thyrotropin receptor. Biochem Biophys Res Commun 1996; 223: 193–8.
10.1006/bbrc.1996.0868
CASPubMedWeb of Science®Google Scholar
11 Nannipieri M, Cecchetti F, Anselmino M, Camastra S, Niccolini P, Lamacchia M et al. Expression of thyrotropin and thyroid hormone receptors in adipose tissue of patients with morbid obesity and/or type 2 diabetes: effects of weight loss. Int J Obes (Lond) 2009; 33: 1001–6.
10.1038/ijo.2009.140
CASPubMedWeb of Science®Google Scholar
12 Lu M, Lin RY. TSH stimulates adipogenesis in mouse embryonic stem cells. J Endocrinol 2008; 196: 159–69.
10.1677/JOE-07-0452
CASPubMedWeb of Science®Google Scholar
13 Zhang L, Baker G, Janus D, Paddon CA, Fuhrer D, Ludgate M. Biological effects of thyrotropin receptor activation on human orbital preadipocytes. Invest Ophthalmol Vis Sci 2006; 47: 5197–203.
10.1167/iovs.06-0596
PubMedWeb of Science®Google Scholar
14 Simons PC, Algra A, van de Laak MF, Grobbee DE, van der GY. Second manifestations of ARTerial disease (SMART) study: rationale and design. Eur J Epidemiol 1999; 15: 773–81.
10.1023/A:1007621514757
CASPubMedWeb of Science®Google Scholar
15 Stolk RP, Wink O, Zelissen PM, Meijer R, van Gils AP, Grobbee DE. Validity and reproducibility of ultrasonography for the measurement of intra-abdominal adipose tissue. Int J Obes Relat Metab Disord 2001; 25: 1346–51.
10.1038/sj.ijo.0801734
CASPubMedWeb of Science®Google Scholar
16 Asvold BO, Bjoro T, Nilsen TI, Vatten LJ. Tobacco smoking and thyroid function: a population-based study. Arch Intern Med 2007; 167: 1428–32.
10.1001/archinte.167.13.1428
PubMedWeb of Science®Google Scholar
17 Knudsen N, Laurberg P, Rasmussen LB, Bulow I, Perrild H, Ovesen L et al. Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the population. J Clin Endocrinol Metab 2005; 90: 4019–24.
10.1210/jc.2004-2225
CASPubMedWeb of Science®Google Scholar
18 Ross R. Atherosclerosis–an inflammatory disease. N Engl J Med 1999; 340: 115–26.
10.1056/NEJM199901143400207
CASPubMedWeb of Science®Google Scholar
19 Fain JN, Tagele BM, Cheema P, Madan AK, Tichansky DS. Release of 12 Adipokines by Adipose Tissue, Nonfat Cells, and Fat Cells From Obese Women. Obesity (Silver Spring) 2010; 18: 890–6.
10.1038/oby.2009.335
CASPubMedWeb of Science®Google Scholar
20 Antunes TT, Gagnon A, Chen B, Pacini F, Smith TJ, Sorisky A. Interleukin-6 release from human abdominal adipose cells is regulated by thyroid-stimulating hormone: effect of adipocyte differentiation and anatomic depot. Am J Physiol Endocrinol Metab 2006; 290: E1140–4.
10.1152/ajpendo.00516.2005
CASPubMedWeb of Science®Google Scholar
21 Antunes TT, Gagnon A, Langille ML, Sorisky A. Thyroid-stimulating hormone induces interleukin-6 release from human adipocytes through activation of the nuclear factor-kappaB pathway. Endocrinology 2008; 149: 3062–6.
10.1210/en.2007-1588
CASPubMedWeb of Science®Google Scholar
22 Choi SH, Lee YJ, Park YJ, Kim KW, Lee EJ, Lim S et al. Retinol binding protein-4 elevation is associated with serum thyroid-stimulating hormone level independently of obesity in elderly subjects with normal glucose tolerance. J Clin Endocrinol Metab 2008; 93: 2313–8.
10.1210/jc.2007-2536
CASPubMedWeb of Science®Google Scholar
23 Kim MS, Small CJ, Stanley SA, Morgan DG, Seal LJ, Kong WM et al. The central melanocortin system affects the hypothalamo-pituitary thyroid axis and may mediate the effect of leptin. J Clin Invest 2000; 105: 1005–11.
10.1172/JCI8857
CASPubMedWeb of Science®Google Scholar
24 Ortega FJ, Moreno-Navarrete JM, Ribas V, Esteve E, Rodriguez-Hermosa JI, Ruiz B et al. Subcutaneous Fat Shows Higher Thyroid Hormone Receptor-alpha1 Gene Expression Than Omental Fat. Obesity (Silver Spring) 2009; 17: 2134–41.
10.1038/oby.2009.110
CASPubMedWeb of Science®Google Scholar
25 van Harmelen V, Reynisdottir S, Eriksson P, Thorne A, Hoffstedt J, Lonnqvist F et al. Leptin secretion from subcutaneous and visceral adipose tissue in women. Diabetes 1998; 47: 913–7.
10.2337/diabetes.47.6.913
CASPubMedWeb of Science®Google Scholar
26 Faber DR, van der GY, Westerink J, Visseren FL. Increased visceral adipose tissue mass is associated with increased C-reactive protein in patients with manifest vascular diseases. Atherosclerosis 2010; 212: 274–80.
10.1016/j.atherosclerosis.2010.04.029
CASPubMedWeb of Science®Google Scholar
27 Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997; 82: 4196–200.
10.1210/jc.82.12.4196
CASPubMedWeb of Science®Google Scholar
28 Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000; 148: 209–14.
10.1016/S0021-9150(99)00463-3
CASPubMedWeb of Science®Google Scholar

Citing Literature

Volume41, Issue2

February 2011

Pages 159-166

The relation between thyroid-stimulating hormone and measures of adiposity in patients with manifest vascular disease

Abstract

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

The relation between thyroid-stimulating hormone and measures of adiposity in patients with manifest vascular disease

Abstract

References

Citing Literature

References

Related

Information